Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection,[1] healing of gastroduodenal ulcers, and treatment of gastritis.[2] It works by enhancing mucosal defense, scavenging free radicals,[3] and temporarily activating genes encoding cyclooxygenase-2.[4]
Clinical data | |
---|---|
Trade names | Mucosta (JP), Rebagen (KR, CN, IN), Rebagit (RU), Rebamax (ID) |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth (tablets) |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C19H15ClN2O4 |
Molar mass | 370.79 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa,[5] and more recently, the small intestine, but not for naproxen-induced gastric damage.[6]
Rebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China[7] and India (where it is marketed under the trade name Rebagen). It is also approved in Russia under the brand name Rebagit.[8]